Dr. Elias Zerhouni, Vice Chairman and President, said the post-transaction remaining BioReference operations represented approximately $300 million in revenue in 2025. He said testing volume in the fourth quarter, excluding the divested oncology assets, grew slightly, and that BioReference reduced its workforce by roughly 29% from the prior year to about 1,400 full-time employees as part of broader operational efficiency initiatives. Management said these changes significantly improved margins and underpin ...

OPKO Health (NasdaqGS:OPK) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker5Hello and welcome to the OPKO Health Fourth Quarter 2025 financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask your question, you may press Star then one on your telephone keypad. To withdraw your question, ...

Performance in 2025 was driven by a 7% top-line increase and 13% adjusted EPS growth, underpinned by deepening health system partnerships that contributed over $1 billion in revenue over three years. Esoteric and specialty testing achieved double-digit growth, serving as a high-margin engine that captures broader routine testing volume once physicians adopt Labcorp for complex diagnostics. The successful integration of Invitae has expanded genetic testing capabilities, with management now viewing it a ...

Core Insights - Labcorp reported a strong performance in 2025 with over 7% revenue growth, 13% adjusted EPS growth, and margin expansion of more than 50 basis points [3][5] - The company highlighted a robust pipeline for mergers and acquisitions (M&A) and a backlog of $8.7 billion in Biopharma Laboratory Services (BLS) [4][11] Financial Performance - Fourth-quarter revenue reached $3.5 billion, up 5.6% year over year, driven by organic growth of 3.8%, acquisitions contributing 1.2%, and foreign currency translation of 0.6% [8] - Adjusted EPS for the fourth quarter was $4.07, reflecting an 18% increase year over year [9] - Free cash flow for the quarter was $490 million, down from $665 million, primarily due to working capital timing [9] Growth Strategy - The company launched over 130 new tests in 2025, focusing on oncology, women's health, neurology, and autoimmune diseases [6][7] - Labcorp's OnDemand service expanded to offer tests for over 200 biomarkers, including food allergies and thyroid health [7] - Management emphasized technology and AI initiatives to enhance efficiency and customer experience, including AI-driven tools for scheduling and reporting [7] M&A Activity - In the fourth quarter, Labcorp completed several acquisitions, including outreach laboratory services from Parkview Health and anatomic pathology assets from Incyte Diagnostics [2] - The company signed or closed 13 deals, contributing over $1 billion in revenue growth over the past three years [2] 2026 Guidance - Labcorp forecasts enterprise revenue growth of 4.7% to 6% for 2026, with adjusted EPS expected to be between $17.65 and $18.25, implying about 9% growth at the midpoint [5][15] - Diagnostics revenue is projected to rise 5% to 6%, with half of the growth expected from volume and half from price/mix [13] - BLS revenue is anticipated to grow 3% to 5%, with Central Labs expected to grow mid-single digits organically [14] Operational Highlights - Diagnostics revenue was $2.7 billion, up 5.5%, with organic growth of 4.1% and acquisitions contributing 1.5% [10] - BLS revenue was $793 million, up 3.4%, with Central Labs revenue growing 11.1% [11] - The company reported a book-to-bill ratio of 1.16 for the quarter, indicating strong demand in Central Labs [12] Leadership Changes - Labcorp announced the upcoming retirement of key executives, with successors appointed under a succession plan [21]

Leadership Transition - Jennifer Erickson has been appointed as Chief Executive Officer-Elect of Sonora Quest Laboratories, succeeding David Dexter who is retiring after over 26 years of service [1][2] - Dexter has been instrumental in the company's growth, leading it to become the market share leader in clinical laboratory testing in Arizona, performing over 100 million diagnostic tests annually [2] Achievements and Contributions - Under Dexter's leadership, significant milestones were achieved, including the development of the My Lab ReQuest™ direct-access testing platform in 2015 and the expansion of COVID-19 diagnostic testing capacity through Operation Catapult in 2020 [3] - Dexter emphasized the importance of collaboration with community partners, enhancing access to diagnostic testing across Arizona [3] Future Direction - Erickson is expected to continue Dexter's legacy of growth and innovation, focusing on patient-centered diagnostics and fostering a culture of collaboration and accountability [4] - With over 20 years of experience in healthcare leadership, including previous roles at Sonora Quest, Erickson is well-positioned to lead the company [5] Company Overview - Sonora Quest Laboratories, a subsidiary of Laboratory Sciences of Arizona, is a joint venture between Banner Health and Quest Diagnostics, recognized as one of the largest integrated laboratory systems in the U.S. [7] - The company employs approximately 3,900 staff and offers a comprehensive range of diagnostic testing services, accredited by the College of American Pathologists [7]

Core Insights - General Motors (GM) shares surged 15% following better-than-expected third-quarter sales and adjusted profit, marking the best performance in the S&P 500 [3][8] - The automotive giant reduced its forecast on tariff costs, indicating a quicker adjustment to tariffs than anticipated by analysts [3] - GM announced a $1.6 billion loss related to a reevaluation of its electric vehicle strategy due to regulatory changes [3] Company Performance - Halliburton (HAL) exceeded third-quarter revenue and adjusted earnings per share estimates, with shares rising approximately 12% [4] - Warner Bros. Discovery (WBD) shares increased by 11% after announcing a strategic review amid interest from potential buyers [5] - Philip Morris International (PM) reported third-quarter revenue and adjusted EPS above forecasts, yet shares fell 3.8% due to high investment levels [9] - Quest Diagnostics (DGX) shares declined 3.1% despite beating revenue and adjusted EPS forecasts, as the company lowered its full-year guidance for reported EPS [10] Market Trends - Major U.S. equities indexes ended the day mixed, with the S&P 500 little changed, the Dow rising 0.5%, and the Nasdaq retreating 0.2% [2] - Gold prices fell over 5%, impacting shares of Newmont (NEM), which dropped more than 9%, the largest decline among S&P 500 stocks [6][8]

Financial Data and Key Metrics Changes - Consolidated revenues for the third quarter were $2.82 billion, reflecting a 13.1% increase year-over-year, with organic revenues growing by 6.8% [15][17] - Reported operating income was $386 million, or 13.7% of revenues, compared to $330 million, or 13.3% of revenues last year [16] - Adjusted EPS was $2.60, up from $2.30 the prior year, while reported EPS was $2.16 compared to $1.99 a year ago [17] Business Line Data and Key Metrics Changes - Revenues for diagnostic information services increased by 13.5%, driven by organic growth across physician, hospital, and consumer channels [15] - In the physician channel, revenue grew approximately 17%, with organic growth in the high single digits [8] - The hospital channel saw low single-digit revenue growth, primarily driven by Co-Lab Solutions [9] Market Data and Key Metrics Changes - Total volume measured by requisitions increased by 12.5% year-over-year, with organic volume up 3.9% [15] - The consumer health business experienced strong growth, with direct channel growth between 30%-40% year-to-date [24][33] Company Strategy and Development Direction - The company is focused on delivering solutions that meet the evolving needs of clinical customers and expanding into consumer life sciences and data analytics [6] - Collaborations with Corewell Health and consumer health brands are expected to support future growth [19] - The company is investing in automation and AI technologies to drive operational improvements [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued strong demand for clinical solutions and the potential for revenue growth in the consumer health segment [3][19] - The company raised its full-year 2025 guidance, expecting revenues between $10.96 billion and $11 billion [18] - Management highlighted the potential impact of PAMA reforms and the need for legislative action to avoid significant payment cuts [5][26] Other Important Information - The company received FDA Breakthrough Device designation for its Haystack MRD test, reinforcing its cancer monitoring innovation [11] - The partnership with Epic Systems for Project Nova aims to modernize the order-to-cash process over the next several years [14][75] Q&A Session Summary Question: Utilization backdrop and expectations into year-end - Management noted that raw REC volume was up 3.9%, with strong demand in various states contributing to growth [23] Question: Latest expectations on PAMA - Management indicated that while the RESULTS Act has been proposed, a delay in PAMA is more likely than its passage [26] Question: Mix performance relative to expectations - Management stated that consumer channels are performing slightly above expectations, with strong growth in wellness and episodic testing [32] Question: 4Q margins and investment impacts - Management expects elevated margins in Q4 but noted potential headwinds from increased employee health expenses and Project Nova investments [40] Question: Cash flow and one-time benefits - Management highlighted strong cash flow but noted that one-time benefits from the CARES Act and tax legislation should not be expected to repeat next year [56] Question: Consumer health momentum and partnerships - Management discussed partnerships with Whoop and Oura, emphasizing the potential for increased requisition volume through these collaborations [62] Question: Oncology initiatives and evidence generation - Management confirmed ongoing studies for the Haystack MRD test and expressed optimism about expanding indications and reimbursement [98]

Financial Data and Key Metrics Changes - Consolidated revenues for the third quarter were $2.82 billion, reflecting a 13.1% increase year-over-year, with organic revenues growing by 6.8% [15] - Reported operating income was $386 million, or 13.7% of revenues, compared to $330 million, or 13.3% of revenues last year; adjusted operating income was $458 million, or 16.3% of revenues, compared to $385 million, or 15.5% last year [16] - Reported EPS was $2.16, up from $1.99 a year ago; adjusted EPS was $2.60 versus $2.30 the prior year [17] - Cash from operations increased to $1.42 billion year-to-date, a 63.1% increase from $870 million in the prior year [17] Business Line Data and Key Metrics Changes - In the physician channel, revenue grew approximately 17%, with organic revenue growth in the high single digits, driven by broad-based demand for clinical solutions [8] - Revenues in the hospital channel grew in low single digits, with COLAB Solutions contributing to growth [9] - The consumer channel saw strong double-digit growth, particularly from the questhealth.com platform and partnerships with companies like Whoop and Oura Health [10] Market Data and Key Metrics Changes - Total volume measured by requisitions increased by 12.5% year-over-year, with organic volume up 3.9% [15] - Revenue per requisition increased by 0.8% year-over-year, driven by an increase in the number of tests per requisition [16] Company Strategy and Development Direction - The company is focused on delivering solutions that meet the evolving needs of core clinical customers and expanding into higher growth areas such as consumer life sciences and data analytics [6] - Strategic acquisitions are emphasized as key growth drivers, particularly in hospital outreach and independent labs [7] - The company announced a joint venture with Corewell Health to establish a laboratory services partnership in Michigan, which is expected to generate approximately $1 billion in annual revenues from COLAB Solutions once fully scaled [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued strong demand for clinical solutions and the execution of their strategy, raising the full-year 2025 guidance [3][19] - The management highlighted the potential impact of PAMA reforms and the need for legislative action to avoid significant payment cuts [5] - The company expects to continue seeing elevated utilization levels and strong performance in the consumer health channel [24] Other Important Information - The company received FDA Breakthrough Device designation for its Haystack MRD test, reinforcing its cancer monitoring innovation [11] - The partnership with Epic Systems aims to modernize the order-to-cash process, enhancing patient and provider experiences [14][75] Q&A Session Summary Question: Utilization backdrop and expectations into year-end - Management noted that raw REC volume was up 3.9%, with strong growth in autoimmune and advanced cardiometabolic testing, and expects utilization levels to continue into Q4 [23] Question: Latest expectations on PAMA - Management indicated that while the RESULTS Act has been proposed, a delay in PAMA is more likely than its passage, with a potential $100 million impact next year [26] Question: Mix performance relative to expectations - Management stated that consumer channels are performing slightly above expectations, with strong growth in episodic testing and wellness testing [32] Question: Q4 margins and Project Nova investments - Management expects elevated margins in Q4 but noted potential headwinds from increased employee health expenses and Project Nova investments [39] Question: Cash flow and one-time benefits - Management highlighted strong cash flow but noted that some one-time benefits, such as the CARES Act payment, are not expected to recur next year [56] Question: Consumer health momentum and partnerships - Management discussed partnerships with Whoop and Oura, emphasizing the potential for increased requisition volume through these collaborations [62] Question: Oncology initiatives and Haystack integration - Management confirmed that the Haystack MRD test is fully integrated and ongoing studies are expected to broaden coverage for multiple cancer indications [98]

Financial Data and Key Metrics Changes - Consolidated revenues for Q3 2025 were $2,820 million, reflecting a 13.1% increase year-over-year, with organic revenue growth of 6.8% [13][16] - Reported operating income was $386 million, or 13.7% of revenues, compared to $330 million, or 13.3% of revenues last year [15][16] - Adjusted EPS for the quarter was $2.60, up from $2.30 a year ago, while reported EPS was $2.16 compared to $1.99 last year [16] - Cash from operations increased to $1,420 million year-to-date, a 63.1% increase from the prior year [17] Business Line Data and Key Metrics Changes - Revenues for Diagnostic Information Services increased by 13.5%, driven by organic growth across physician, hospital, and consumer channels [13] - The physician channel saw approximately 17% revenue growth, with organic growth in the high single digits [4][5] - The hospital channel experienced low single-digit revenue growth, supported by collaborative lab solutions [6] - The consumer channel showed strong double-digit growth, particularly from the questhealth.com platform [7][8] Market Data and Key Metrics Changes - Total volume measured by requisitions increased by 12.5% year-over-year, with organic volume up 3.9% [13][14] - The company noted broad-based demand across clinical solutions, particularly in advanced diagnostics areas such as autoimmune and brain health [4][9] Company Strategy and Development Direction - The company is focused on delivering solutions that meet the evolving needs of core clinical customers and expanding into higher growth areas like consumer health and data analytics [3][4] - Recent acquisitions are emphasized as key growth drivers, particularly in hospital outreach and independent labs [4] - The company is investing in automation and AI to improve operational efficiency and customer experience [11] Management's Comments on Operating Environment and Future Outlook - Management raised the full-year 2025 guidance due to strong performance year-to-date, expecting revenues between $10,960 million and $11,000 million [17][18] - The company is optimistic about potential PAMA reforms, although the passage of the Results Act is uncertain [2][27] - Management expects continued strong demand for clinical solutions and a positive outlook for the consumer health channel [20][36] Other Important Information - The company announced a joint venture with CoreWell Health to establish lab services in Michigan, which is expected to generate approximately $1 billion in annual revenues once fully scaled [7][18] - The company is implementing Project Nova, a multi-year order to cash transformation, with significant investments expected in 2025 [11][18] Q&A Session Summary Question: Utilization backdrop and expectations into year-end - Management noted that raw requisition volume was up 3.9%, with strong growth in autoimmune and advanced cardiometabolic testing, and expects utilization levels to continue into Q4 [22][24][26] Question: Latest expectations on PAMA - Management indicated a likelihood of a PAMA delay, with a potential $100 million impact if PAMA is reinstated, but they can offset some of this impact through controlled investments [27][28] Question: Mix performance relative to expectations - Management stated that consumer channels are performing slightly above expectations, with strong growth in episodic testing and wellness testing [32][34][36] Question: Q4 margins and impacts - Management highlighted strong Q3 margins but noted elevated employee health expenses and increased investments in Project Nova as potential headwinds for Q4 [40][44] Question: Cash flow and one-time benefits - Management confirmed strong cash flow guidance of $1,800 million, noting one-time benefits from the CARES Act and recent tax legislation that may not recur in 2026 [60][62] Question: Consumer health momentum and partnerships - Management discussed partnerships with WHOOP and Aura, highlighting the potential for significant growth in the consumer health segment [68][71] Question: Oncology initiatives and Haystack integration - Management provided updates on the integration of the Haystack MRD test and ongoing studies to expand its indications, with positive market response expected [96][98][112]

Core Insights - Alger Weatherbie Specialized Growth Fund's second-quarter 2025 investor letter highlights the impact of trade policy uncertainty on market volatility, particularly due to President Trump's tariffs, which affected import-dependent companies [1] - The S&P 500 reached a record high by the end of Q2 2025, with a gain of 10.94%, aided by improved market sentiment following the suspension of reciprocal tariff hikes on China [1] - Class A shares of the fund outperformed the Russell 2500 Growth Index during the same period [1] Company Analysis: NeoGenomics, Inc. - NeoGenomics, Inc. is identified as a leading provider of specialty oncology lab testing services, with a focus on serving hospitals, oncologists, and pathologists [3] - The stock of NeoGenomics experienced a one-month return of 14.83%, but it has lost 45.66% of its value over the past 52 weeks, closing at $8.13 per share with a market capitalization of $1.05 billion as of September 23, 2025 [2] - Despite a revenue shortfall attributed to weakness in non-clinical segments, NeoGenomics exceeded consensus estimates for EBITDA and reaffirmed its full-year 2025 organic revenue guidance, while slightly increasing total revenue guidance due to a recent acquisition [3]